Products Azathioprine is commercially available as film-coated tablets and as a lyophilizate (Imurek, generic). It has been approved in many countries since 1965. Structure and properties Azathioprine (C9H7N7O2S, Mr = 277.3 g/mol) is a nitromidazole derivative of mercaptopurine. It exists as a pale yellow powder that is practically insoluble in water. Effects Azathioprine (ATC L04AX01) … Azathioprine (Imuran)
Products Risankizumab was approved in the United States and in many countries in 2019 as a solution for injection (Skyrizi). Structure and properties Risankizumab is a humanized IgG1 monoclonal antibody produced by biotechnological methods. Effects Risankizumab (ATC L04AC) has selective immunosuppressive and anti-inflammatory properties. The antibody binds to the p19 subunit of human interleukin-23 (IL-23), … Risankizumab
Products Infliximab is commercially available as a powder for a concentrate for the preparation of an infusion solution (Remicade, biosimilars: Remsima, Inflectra). It has been approved in many countries since 1999. Biosimilars were released in 2015. Structure and properties Infliximab is a chimeric human murine IgG1κ monoclonal antibody with a molecular mass of 149.1 kDa … Infliximab: Drug Effects, Side Effects, Dosage and Uses
Products Cortisone tablets are medicinal products which are intended for ingestion and contain active substances from the group of glucocorticoids. The tablets, water-soluble tablets and sustained-release tablets are usually monopreparations, which are often divisible. Glucocorticoids were first used medicinally in the late 1940s. Structure and properties The glucocorticoids contained in the drugs are derived from … Cortisone Tablets Effects and Side Effects
Products Ocrelizumab was approved in many countries and in the United States in 2017 and in the EU in 2018 as an infusion concentrate (Ocrevus). Structure and properties Ocrelizumab is a humanized IgG1 monoclonal antibody with a molecular mass of 145 kDa. It is produced by biotechnological methods. Ocrelizumab is the successor agent to rituximab … Ocrelizumab
Products Abatacept is commercially available as an injection and infusion preparation (Orencia). It was approved in the United States in 2005 and in the EU and many countries in 2007. Structure and properties Abatacept is a recombinant fusion protein with the following components: Extracellular domain of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). Modified Fc domain of … Abatacept
Products Satralizumab was approved in many countries in 2020 as a solution for injection (Enspryng). Structure and properties Satralizumab is a humanized IgG2 monoclonal antibody produced by biotechnological methods. Effects Satralizumab (ATC L04AC19) has anti-inflammatory and immunosuppressive properties. The effects are due to binding to the soluble and membrane-bound human IL-6 receptor (IL-6R), preventing signal … Satralizumab
Products Anti-allergy medications are available in numerous dosage forms. These include tablets, capsules, solutions, suspensions, nasal sprays, eye drops, inhalation preparations, and injectables. Structure and properties Antiallergic drugs do not have a uniform chemical structure. However, several groups within the class can be identified (see below). Effects Antiallergic drugs have antiallergic, antiinflammatory, immunosuppressive, antihistamine, and … Antiallergics
Products Ofatumumab was approved in 2009 as a concentrate for the preparation of an infusion solution for leukemia treatment (Arzerra). In 2020, a solution for injection was approved in the United States for MS treatment (Kesimpta). Structure and properties Ofatumumab is a human IgG1 monoclonal antibody produced by biotechnological methods. It has a molecular mass … Ofatumumab
Products Golimumab is commercially available as a solution for injection (Simponi). It was approved in many countries in 2010. Structure and properties Golimumab (Mr = 150 kDa) is a human IgG1κ-monoclonal antibody. Effects Golimumab (ATC L04AB06) has selective immunosuppressive and anti-inflammatory properties. The effects are based on binding to the soluble and membrane-bound proinflammatory cytokine … Golimumab
Products TNF-α inhibitors are commercially available as injectable and infusion preparations. Infliximab (Remicade) was the first agent from this group to be approved in 1998, and in many countries in 1999. Biosimilars of some representatives are now available. Others will follow in the next few years. This article refers to biologics. Small molecules can also … TNF-Α Inhibitors
Products Tacrolimus is commercially available in the form of capsules, sustained-release capsules, sustained-release tablets, as a concentrated solution for infusion, as granules, and as an ointment (Prograf, generic, Advagraf, Protopic, generic, Modigraf). It has been approved in many countries since 1996. This article refers to oral use; see also Topical Tacrolimus (Protopic Ointment). Structure and … Tacrolimus (Protopic, Prograf): Drug Effects, Side Effects, Dosage and Uses
